B
Bull
Bull · 25%THRD
$5.15
情境價格
$5.380
-0.005 (-0.09%)收盤時
Loading chart…
- High
- 5.430
- Open
- 5.410
- VWAP
- 5.38
- Vol
- 1.42M
- Mkt Cap
- 524.97M
- Low
- 5.345
- Amount
- 7.64M
- EV/EBITDA, TTM
- 2.32
Third Harmonic Bio, Inc. is a biopharmaceutical company. The Company is focused on advancing the next wave of medicine for inflammatory diseases through the development of novel, small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. It is developing medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. Its lead product candidate, THB335, is a titratable, oral, small molecule inhibitor. Dysfunctional mast cell activity has been implicated in the pathophysiology of a broad range of mast cell driven inflammatory disorders, including urticaria, asthma and gastrointestinal disorders, among others. THB335 maintains the nonclinical pharmacology and selectivity profile of THB001, with structural modifications that are designed to functionally block the site of reactive metabolite formation to mitigate hepatotoxicity risk.
估值指標
The current forward P/E ratio for Third Harmonic Bio Inc (THRD) is -3.64, compared to its 5-year average forward P/E of -6.92.
Alphio AI Price Scenarios for THRD
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
事件時間軸
資訊
9.006-12NewsfilterThird Harmonic Bio Announces Stockholder Approval of Plan of Liquidation and Dissolution, Updated THB335 Phase 1 Clinical Data, and Initiation of Sale of THB335
2.004-15BenzingaTop 3 Health Care Stocks You May Want To Dump This Quarter
9.004-14BenzingaThird Harmonic Bio Stock Is Up 40% Monday: What's Happening?
2.004-14BenzingaThird Harmonic Bio, Apple, Dell And Other Big Stocks Moving Lower In Monday's Pre-Market Session
9.004-14SeekingAlphaThird Harmonic Bio plans to liquidate the company, sell urticaria treatment
THRD FAQ — answered by Alphio AI
Third Harmonic Bio, Inc. is a biopharmaceutical company. The Company is focused on advancing the next wave of medicine for inflammatory diseases through the development of novel, small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. It is developing medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. Its lead product candidate, THB335, is a titratable, oral, small molecule inhibitor. Dysfunctional mast cell activity has been implicated in the pathophysiology of a broad range of mast cell driven inflammatory disorders, including urticaria, asthma and gastrointestinal disorders, among others. THB335 maintains the nonclinical pharmacology and selectivity profile of THB001, with structural modifications that are designed to functionally block the site of reactive metabolite formation to mitigate hepatotoxicity risk. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。